GRAd-COV2 Uses, Dosage, Side Effects and more
GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2). Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses.
Trade Name | GRAd-COV2 |
Generic | GRAd-COV2 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |